StreetAlpha.app
Home › Stocks › ALZN

Alzamend Neuro, Inc. (ALZN)

$0.78
▼ −23.94%
LAST CLOSE · NOV 20

Alzamend Neuro is a clinical stage drug developer in Atlanta working on treatments for Alzheimer's and other brain disorders. It last closed at $0.78 on Nov 20, down 23.94% on the day. For the quarter ended Jul 2026, ALZN reported EPS of -$0.68. Over its last 3 reports the stock moved an average of 4.3% the session after earnings. Over the last 12 months ALZN insiders bought $109K of stock on the open market and sold $14K, according to SEC Form 4 filings.

AI Auto Pilots
Is ALZN in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold ALZN.

Key Stats

Last 12 months
Results
Net income
−$9.1M
EPS (diluted)
−$2.03
Valuation
Market cap
$3.7M
4.8M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$7.6M
At Jul 31
Shareholder equity
$5.8M
Shares outstanding
4.8M
At Sep 10
Fiscal year endsApril
ExchangeNasdaq
Financials history
FY2022: −$12.4M−$12.4MFY2022FY2023: −$14.9M−$14.9MFY2023FY2024: −$9.9M−$9.9MFY2024FY2025: −$4.5M−$4.5MFY2025FY2026: −$8.8M−$8.8MFY2026

From ALZN's SEC filings, latest 10-Q for the period ending Jul 31, 2026 (filed Sep 10). Last 12 months adds up the four latest quarters.

Last report
Jul 23
2025 · next date not set yet
Reported EPS
-$0.68
Quarter ended Jul 2026
Year ago EPS
-$1.28
Same quarter last year
Revenue
—
Last reported quarter
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Oct 2024: -$3.61Oct '24Jan 2025: -$1.75Jan '25Apr 2025: -$1.78Apr '25Jul 2025: -$1.28Jul '25Oct 2025: -$0.30Oct '25Jan 2026: -$0.58Jan '26Apr 2026: -$0.74Apr '26Jul 2026: -$0.68Jul '26Latest -$0.68
Revenue by quarter
Not enough quarters on file yet.
How ALZN moved after its last 3 reports
Average move the session after a report ±4.3%
Jul 23, 2025After the close−0.7%
Dec 12, 2024After the close0.0%
Mar 16, 2023After the close−12.4%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on ALZNStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on ALZN
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on ALZN

Technical Analysis

ALZN · as of the Nov 20 close · updated each morning
Downtrend, oversold

The stock is 60% below its 20 day and 83% below its 50 day average. It is 81% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 22), oversold. The nearest support is the 52 week low at $0.75, and the nearest resistance the Pivot at $0.84.

Short trendBearish
Long trendBearish
MomentumWeak
StretchOversold
VolatilityHigh, 19.7%/day
Key levels
$2.5452 week high+225.6%
$1.4250 day average+82.1%
$1.42100 day average+82.1%
$1.41200 day average+80.8%
$1.2420 day average+59.0%
$1.24Swing high (May 29)+59.0%
$0.93Pivot R1+19.2%
$0.84Pivot+7.7%
$0.78Last close
$0.7552 week low−3.8%
$0.69Pivot S1−11.5%
Indicators
RSI (14)22.50Oversold below 30Oversold
MACD-0.10Below its signal lineBearish
Stochastic3.4Near the bottom of its rangeOversold
ADX (14)26.3Trending down
Williams %R-97.5Oversold below −80, overbought above −20Oversold
CCI (20)-209.4Oversold below −100, overbought above 100Oversold
Rate of change−45.0%Change over 10 sessionsBearish
ATR (14)$0.15Typical daily range, 19.7% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for ALZN

What happened before

See how ALZN did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow ALZN usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How ALZN has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2021.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for ALZNHow many large options trades hit ALZN, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

ALZN Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ▲7 buying vs 3 selling
  • ▼Held by funds -0.6 pts
  • ▲Funds holding +4
  • ▲Superinvestors: 1 added, 0 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding1511+36.4%
In funds' top 1000–
Held by funds28.2%28.8%−0.6 pts
New / increased4 / 31 / 2+133.3%
Reduced / sold out3 / 04 / 3−57.1%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See ALZN institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

ALZN Insider Trading

All filings →
Insider trading · 12 months
Insiders are net buyers
Bought$109K1 buy · 1 insider
Sold$14K3 sales · 2 insiders
2025-12 sold $11K2026-04 bought $109K2026-08 sold $3KDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Aug 26Milton C Ault IIIDirectorSale2,000$1.56$3K
Apr 14Milton C Ault IIIDirectorBuy108,388$1.00$109K
Dec 23, 2025Milton C Ault IIIDirectorSale1,851$2.07$4K
Dec 19, 2025William B. HorneDirectorSale3,333$2.12$7K
Oct 23, 2025Lynne Fahey McGrathDirectorSale30$2.29$69
Oct 9, 2025Milton C Ault IIIDirectorSale121,791$2.42$295K
Every insider buy and sale for ALZN over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See ALZN insider trades →

From SEC Form 4 filings by ALZN's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ALZN is in one of them and how their past ALZN trades turned out.

ALZN in the AI portfolios
Loading…

ALZN News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered ALZN in an article yet. Here's the latest on the wider market.

ALZN in the news

About Alzamend Neuro

Alzamend Neuro is a clinical stage drug developer based in Atlanta, Georgia, focused on brain disorders. It is working on treatments for Alzheimer's disease, bipolar disorder, major depressive disorder and post traumatic stress disorder. Its lead candidate, AL001, is a form of lithium designed to treat these conditions, and it is in human clinical trials. Its target patients are people living with these illnesses.

Headquarters
Atlanta, GA